Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045992037> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2045992037 endingPage "e75027" @default.
- W2045992037 startingPage "e75027" @default.
- W2045992037 abstract "Background Cough is listed as an adverse drug reaction (ADR) on the labels of angiotensin receptor blockers (ARB). However, a causal association with cough has also been reported for angiotensin converting enzyme inhibitors (ACEI), which have frequently been used as comparator drugs in the registration clinical trials of ARBs. This prompted us to examine the possible influence of using comparator drugs with well-known ADRs on the safety reporting of investigational drugs in blinded randomized clinical trials. Methods and Findings The double-blinded, randomized clinical trials with comparator drugs were identified in the Japanese dossiers for the new drug applications of ARBs. The risk ratios (RR) of reporting cough and headache in ARB arms were calculated for each ARB by comparing trials using ACEIs and trials using non-ACEIs, were then combined with a meta-analysis. 23 trials with a total of 6643 patients were identified, consisting 6 trials using an ACEI comparator including 819 ARB patients and 17 trials using a non-ACEI comparator including 5824 ARB patients. The combined RR of cough reporting was significantly elevated (20.77; 95% confidence interval [CI], 7.47 to 57.76), indicating more frequent reporting of cough in clinical trials using an ACEI comparator. In contrast, the combined RR of headache, a negative control, was insignificant (1.45; 95% CI, 0.34 to 6.22). Conclusion The use of comparators with well-known ADRs in blinded randomized trials produces potential bias in the reporting frequency of ADRs for investigational drugs. The selection of appropriate comparator drugs should be critical in unbiased safety assessment in double-blinded, randomized clinical trials and thus have relevance in reviewing the safety results from a regulatory point of view." @default.
- W2045992037 created "2016-06-24" @default.
- W2045992037 creator A5037731704 @default.
- W2045992037 creator A5054564290 @default.
- W2045992037 creator A5086037678 @default.
- W2045992037 date "2013-09-23" @default.
- W2045992037 modified "2023-09-27" @default.
- W2045992037 title "Biased Safety Reporting in Blinded Randomized Clinical Trials: Meta-Analysis of Angiotensin Receptor Blocker Trials" @default.
- W2045992037 cites W1980915464 @default.
- W2045992037 cites W1988100739 @default.
- W2045992037 cites W2006408873 @default.
- W2045992037 cites W2015805851 @default.
- W2045992037 cites W2042805913 @default.
- W2045992037 cites W2107328434 @default.
- W2045992037 cites W2119156782 @default.
- W2045992037 cites W2125435699 @default.
- W2045992037 cites W2126930838 @default.
- W2045992037 cites W2133354801 @default.
- W2045992037 cites W4294215472 @default.
- W2045992037 doi "https://doi.org/10.1371/journal.pone.0075027" @default.
- W2045992037 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3781030" @default.
- W2045992037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24086427" @default.
- W2045992037 hasPublicationYear "2013" @default.
- W2045992037 type Work @default.
- W2045992037 sameAs 2045992037 @default.
- W2045992037 citedByCount "5" @default.
- W2045992037 countsByYear W20459920372014 @default.
- W2045992037 countsByYear W20459920372015 @default.
- W2045992037 countsByYear W20459920372016 @default.
- W2045992037 countsByYear W20459920372022 @default.
- W2045992037 crossrefType "journal-article" @default.
- W2045992037 hasAuthorship W2045992037A5037731704 @default.
- W2045992037 hasAuthorship W2045992037A5054564290 @default.
- W2045992037 hasAuthorship W2045992037A5086037678 @default.
- W2045992037 hasBestOaLocation W20459920371 @default.
- W2045992037 hasConcept C126322002 @default.
- W2045992037 hasConcept C168563851 @default.
- W2045992037 hasConcept C197934379 @default.
- W2045992037 hasConcept C44249647 @default.
- W2045992037 hasConcept C535046627 @default.
- W2045992037 hasConcept C71924100 @default.
- W2045992037 hasConcept C82789193 @default.
- W2045992037 hasConcept C95190672 @default.
- W2045992037 hasConcept C98274493 @default.
- W2045992037 hasConceptScore W2045992037C126322002 @default.
- W2045992037 hasConceptScore W2045992037C168563851 @default.
- W2045992037 hasConceptScore W2045992037C197934379 @default.
- W2045992037 hasConceptScore W2045992037C44249647 @default.
- W2045992037 hasConceptScore W2045992037C535046627 @default.
- W2045992037 hasConceptScore W2045992037C71924100 @default.
- W2045992037 hasConceptScore W2045992037C82789193 @default.
- W2045992037 hasConceptScore W2045992037C95190672 @default.
- W2045992037 hasConceptScore W2045992037C98274493 @default.
- W2045992037 hasIssue "9" @default.
- W2045992037 hasLocation W20459920371 @default.
- W2045992037 hasLocation W20459920372 @default.
- W2045992037 hasLocation W20459920373 @default.
- W2045992037 hasLocation W20459920374 @default.
- W2045992037 hasOpenAccess W2045992037 @default.
- W2045992037 hasPrimaryLocation W20459920371 @default.
- W2045992037 hasRelatedWork W1885119863 @default.
- W2045992037 hasRelatedWork W2114346778 @default.
- W2045992037 hasRelatedWork W2335438131 @default.
- W2045992037 hasRelatedWork W2531052508 @default.
- W2045992037 hasRelatedWork W2592774827 @default.
- W2045992037 hasRelatedWork W2626084264 @default.
- W2045992037 hasRelatedWork W2762279224 @default.
- W2045992037 hasRelatedWork W2903890959 @default.
- W2045992037 hasRelatedWork W4212933565 @default.
- W2045992037 hasRelatedWork W4379197432 @default.
- W2045992037 hasVolume "8" @default.
- W2045992037 isParatext "false" @default.
- W2045992037 isRetracted "false" @default.
- W2045992037 magId "2045992037" @default.
- W2045992037 workType "article" @default.